A Randomized Placebo-Controlled Clinical Trial of Nicotinamide Riboside in Obese Men: Safety, Insulin-Sensitivity, and Lipid-Mobilizing Effects

Objective

To test the safety of dietary NR supplementation and its potential to improve insulin sensitivity and other metabolic parameters in obese, insulin-resistant men.

Study Design

Randomized, double-blind, placebo-controlled, parallel assignment study in 40 healthy, obese sedentary men

Dose

2000 mg

Duration

12 weeks

Key Outcomes

  • NR-supplemented subjects had an average 2% absolute reduction in liver fat content compared to a 0.2% absolute reduction in the placebo group.

  • Of the subset of men who started the trial with greater than 5% liver fat, 69% experienced a reduction in liver fat compared to only 39% of the men taking the placebo.

  • NR supplementation tended to decrease circulating levels of alanine aminotransferase (ALT) in the blood.

Clinical, Pharmacokinetic/Safety, Liver Health, Metabolic HealthANAD Staff